XML 77 R64.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration and License Agreements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
Jul. 31, 2021
Oct. 31, 2020
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Sep. 30, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Common stock, value $ 645,000     $ 645,000       $ 645,000   $ 573,000  
Common stock, shares issued 65,045,313     65,045,313       65,045,313   58,446,016  
Research and development expense       $ 45,577,000   $ 19,354,000   $ 235,683,000 $ 40,903,000    
Collaboration receivable $ 50,000,000     $ 50,000,000       $ 50,000,000   $ 0  
Common Stock                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Shares issued and sold     5,750,000 1,761,285 2,795,700   12,176,471        
Prime Medicine Inc                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaborative arrangement rights and obligations, description               The Company had an obligation to issue $5.0 million in shares of its common stock to Prime Medicine, and Prime Medicine had an obligation to issue 5,000,000 shares of its common stock to the Company, should the Company elect to extend the collaboration beyond one year      
Obligation to issue common stock value                     $ 5,000,000.0
Obligation to issue common stock shares                     5,000,000
Prime Medicine Inc | Common Stock                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Shares issued and sold     200,307                
Number of common stock received     5,000,000                
Prime Medicine Inc | Common Stock Issued                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Research and development expense                   5,500,000  
Prime Medicine Inc | Common Stock Received                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Research and development expense offset amount                   $ 100,000  
Apellis Pharmaceuticals, Inc                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Agreement description               On June 30, 2021, the Company entered into a master research and collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company’s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company will apply certain of its base editing technology and conduct preclinical research on up to six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis will have exclusive rights to license each of the six programs (each an “Opt-In Right”) and will assume responsibility for subsequent development. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program licensed under the collaboration. The collaboration will be managed on an overall basis by an Alliance Steering Committee, or ASC, formed by an equal number of representatives from the Company and Apellis.      
Collaboration arrangement, initial term 5 years                    
Deferred revenue liability $ 50,000,000.0     $ 50,000,000.0       $ 50,000,000.0      
Collaboration receivable 50,000,000.0     50,000,000.0       50,000,000.0      
Collaboration arrangement, amount received               0      
Collaboration agreement aggregate transaction price 75,000,000.0     75,000,000.0       75,000,000.0      
Upfront fee due upon signing contract 50,000,000.0     50,000,000.0       50,000,000.0      
Collaboration agreement first anniversary amount due 25,000,000.0     25,000,000.0       25,000,000.0      
Apellis Pharmaceuticals, Inc | ASC 606                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Contract asset 25,000,000.0     25,000,000.0       25,000,000.0      
Deferred revenue liability $ 25,000,000.0     $ 25,000,000.0       $ 25,000,000.0      
Apellis Pharmaceuticals, Inc | Maximum                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration arrangement extension term 2 years                    
Apellis Pharmaceuticals, Inc | Subsequent Event                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration arrangement, amount received   $ 50,000,000.0